Takeda acquires vaccine maker Inviragen

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of $35 million, and future payments of up to $215 million linked to the progress of clinical development and achievement of key commercial milestones. Inviragen has created innovative products using its expertise in viral vaccines. The company's lead candidate, DENVax, is a four-strain recombinant viral vaccine for the prevention of Dengue infection. An administration schedule of two doses of DENVax over 90 days is currently being evaluated in Phase II clinical trials.